Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01875666
Title Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib
Recruitment Completed
Gender female
Phase Phase I
Variant Requirements No
Sponsors UNC Lineberger Comprehensive Cancer Center
Indications

Her2-receptor positive breast cancer

Therapies

Lapatinib + Trastuzumab

Trastuzumab

Pertuzumab

Pertuzumab + Trastuzumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.